Concepedia

Author

Carl Hay

Research Institute for Genetic and Human Therapy

Also Known As

Carl Hay, Carl M. Hay

28

Publications

2.5K

Citations

17

H-Index

50

Concepts

All Affiliations

Research Institute for Genetic and Human TherapyAstraZeneca (United States)The University of QueenslandNovartis (United States)QIMR Berghofer Medical Research Institute
CH

About

Carl Hay is an author at Research Institute for Genetic and Human Therapy specializing in medicine, tumor biology, and immunology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

10

10

1.3K

2

Cell Biology

6

6

557

3

Natural Sciences

2

2

49

4

Biomolecular Engineering

2

2

49

5

Biochemistry

1

1

19

Carl Hay

×

19

Publications

2.5K

Citations

17

H-Index

YearCitations

Dopaminergic Neurons Protected from Degeneration by GDNF Gene Therapy

DL Choi-Lundberg, Qing Lin, Yung‐Nien Chang,

Science

1997

631

Complete genome sequence analysis of Seneca Valley virus-001, a novel oncolytic picornavirus

Laura M. Hales, Nick J. Knowles, P. Seshidar Reddy,

Journal of General Virology

2008

374

Co-inhibition of CD73 and A2AR Adenosine Signaling Improves Anti-tumor Immune Responses

Arabella Young, Shin Foong Ngiow, Deborah S. Barkauskas,

Cancer Cell

2016

373

Targeting CD73 in the tumor microenvironment with MEDI9447

Carl Hay, Erin Sult, Qihui Huang,

OncoImmunology

2016

281

Seneca Valley Virus, a Systemically Deliverable Oncolytic Picornavirus, and the Treatment of Neuroendocrine Cancers

P. Seshidhar Reddy, Kevin D. Burroughs, Laura M. Hales,

JNCI Journal of the National Cancer Institute

2007

250

Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade

Rui Yang, Samah Elsaadi, Kristine Misund,

Journal for ImmunoTherapy of Cancer

2020

114

An oncolytic adenovirus selective for retinoblastoma tumor suppressor protein pathway-defective tumors: dependence on E1A, the E2F-1 promoter, and viral replication for selectivity and efficacy.

John Jakubczak, Patricia C. Ryan, M Gorziglia,

PubMed

2003

99

Identification of anti-tumour biologics using primary tumour models, 3-D phenotypic screening and image-based multi-parametric profiling

Alan M. Sandercock, Steven Rust, Sandrine Guillard,

Molecular Cancer

2015

53

Combining phenotypic and proteomic approaches to identify membrane targets in a ‘triple negative’ breast cancer cell type

Steven Rust, Sandrine Guillard, Kris F. Sachsenmeier,

Molecular Cancer

2013

50

Antitumor efficacy and tumor-selective replication with a single intravenous injection of OAS403, an oncolytic adenovirus dependent on two prevalent alterations in human cancer

Patricia C. Ryan, John Jakubczak, David A. Stewart,

Cancer Gene Therapy

2004

40

Page 1